ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

INVA vs ETON // EV/EBITDA & P/E VALUATION

Innoviva Inc. (NASDAQ) VS. Eton Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: INVA 6 — ETON 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INVA VS. ETON) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC INVA ETON SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 74.80% 53.50% +21.30 INVA /gross-margins <GO>
Return on Invested Capital (ROIC) 14.70% -0.90% +15.60 INVA /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 7.6x — — TIE /valuation <GO>
Free Cash Flow Yield 12.72% 0.66% +12.06 INVA /fcf-yield <GO>
Operating Margin 39.80% -1.10% +40.90 INVA /operating-margins <GO>
Net Profit Margin — -5.80% — TIE /net-margins <GO>
Revenue Growth (YoY) 14.70% 104.90% -90.20 ETON /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 13.37 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 7/9 -1.00 ETON /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.4 47.9 +5.51 INVA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.54B $1.53B $5.5M INVA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR INVA REV ETON REV INVA GROSS % ETON GROSS % INVA FCF ETON FCF
FY 2025 $411.3M $80.0M 74.8% 53.5% $195.8M $10.2M
FY 2024 $358.7M $39.0M 82.6% 60.0% $188.4M $943.0K
FY 2023 $310.5M $31.6M — — $141.1M $6.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INVA // BETA —
ETON // BETA —